After millions received the AstraZeneca vaccine during the Corona Covid-19 pandemic, the manufacturer of the vaccine acknowledged side effects, including blood clots and low platelets.

Developed by the British-Swedish company in collaboration with the University of Oxford, UK, and produced by the Serum Institute of India, Covishield has been widely distributed in over 150 countries, including Britain and India.

Some studies conducted during the pandemic found that the vaccine was 60 to 80 percent effective in protecting against the mutated coronavirus. However, research has since found that Covishield can cause some people to develop blood clots, which can be fatal.

A class action lawsuit filed in the United Kingdom claimed that the vaccine led to deaths and serious injuries and demanded compensation amounting to 100 million pounds sterling for about 50 victims, while one of the complainants claimed that the vaccine caused him permanent brain injury after he suffered a blood clot that prevented him from working.

While AstraZeneca disputed these claims, it admitted for the first time in a court document that the vaccine could "in very rare cases, cause blood clots with thrombocytopenia syndrome, which is characterized by blood clots and low platelet counts in humans.

 The World Health Organization confirmed that Covishield can have life-threatening side effects, noting that "a very rare adverse event called thrombosis has been reported with thrombocytopenia syndrome, which includes unusual and severe blood clotting events associated with a low platelet count, after vaccination with this." the vaccine".